The oncogenic role of hepatitis delta virus in hepatocellular carcinoma

Marc Puigvehí, Carlos Moctezuma-Velázquez, Augusto Villanueva, Josep M. Llovet

Research output: Contribution to journalReview articlepeer-review

29 Scopus citations


Hepatitis delta virus (HDV) is a small defective virus that needs hepatitis B virus (HBV) to replicate and propagate. HDV infection affects 20-40 million people worldwide and pegylated interferon (PegIFN) is the only recommended therapy. There is limited data on the contribution of HDV infection to HBV-related liver disease or liver cancer. Evidence from retrospective and cohort studies suggests that HBV/HDV coinfection accelerates progression to cirrhosis and is associated with an increased risk of hepatocellular carcinoma (HCC) development compared to HBV monoinfection. Although the life cycle of HDV is relatively well known, there is only ancillary information on the molecular mechanisms that can drive specific HDV-related oncogenesis. No thorough reports on the specific landscape of mutations or molecular classes of HDV-related HCC have been published. This information could be critical to better understand the uniqueness, if any, of HDV-related HCC and help identify novel targetable mutations. Herein, we review the evidence supporting an oncogenic role of HDV, the main reported mechanisms of HDV involvement and their impact on HCC development.

Original languageEnglish
Pages (from-to)120-130
Number of pages11
JournalJHEP Reports
Issue number2
StatePublished - Aug 2019


  • HCC, co-infection
  • Hepatitis B virus
  • defective
  • liver cancer
  • molecular pathogenesis
  • superinfection


Dive into the research topics of 'The oncogenic role of hepatitis delta virus in hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this